# Eye Health Supplements Market

> Eye Health Supplements Market Research Report By Ingredient Type (Lutein And Zeaxanthin, Antioxidants, Omega-3 Fatty Acids, Coenzyme Q10, Flavonoids, Alpha-Lipoic Acid, Astaxanthin, and Others), By Form (Capsules, Liquid, Gummies, Softgel, And Others), By Application (Age-Related Macular Degeneration, Cataract, Glaucoma, Eye Fatigue, Corneal Support, Eyelid Conjunctivitis, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Hypermarkets & Supermarkets, and E-Commerce), and By Region (North America, Europe, Asia-Pacific, South America, and Middle East & Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 8.05%
- **2025:** USD 2.91 Billion
- **2035:** USD 6.32 Billion
- **Key Players:** Bausch + Lomb, Alcon, Nestlé Health Science, Amway (Nutrilite), Abbott, Blackmores, H&H Group (Swisse), ZeaVision

**Report ID:** MRFR/HC/7316-CR · **Pages:** 183 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** August 18, 2026

**URL:** https://www.marketresearchfuture.com/reports/eye-health-supplements-market-8788

---

## Market Summary

As per Market Research Future Analysis, the Eye Health Supplements Market was valued at USD 2.42 billion in 2024 and is projected to reach USD 4.93 billion by 2035, growing at a CAGR of 6.69% from 2025 to 2035. The market growth is driven by the increasing prevalence of eye diseases, heightened public awareness of eye health, and the rising demand for [nutritional supplements](https://www.marketresearchfuture.com/reports/nutritional-supplements-market-25113) that support vision. Key ingredients such as lutein vision supplements, zeaxanthin, and omega-3 fatty acids are gaining traction due to their proven benefits in reducing the risk of age-related macular degeneration and other eye conditions. The market is characterized by a competitive landscape with numerous players focusing on product innovation and strategic partnerships.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Aging population and rising AMD prevalence | +1.6 pp | Global (NA, EU, Japan) | Long-term (≥4 yr) | [3] |
| Digital eye strain from prolonged screen exposure | +1.3 pp | Asia-Pacific, North America | Short-term (≤2 yr) | [7] |
| Clinical validation from AREDS2-class evidence | +1.1 pp | North America, Europe | Medium-term (2–4 yr) | [1] |
| Direct-to-consumer subscription economics | +1.0 pp | North America, Europe, China | Short-term (≤2 yr) |   |
| Format innovation in gummies, chews and sachets | +0.9 pp | Asia-Pacific, North America | Medium-term (2–4 yr) | [9] |
| Algal DHA capacity scale-up lowering input cost | +0.7 pp | Global | Medium-term (2–4 yr) | [14] |
| Diabetes-driven retinopathy screening programs | +0.6 pp | Asia-Pacific, MEA | Long-term (≥4 yr) | [4] |

### Demographic Pressure from Age-Related Macular Degeneration

Population aging remains the structural engine of the Eye Health Supplements Market. The Institute for Health Metrics and Evaluation projects the global cohort aged 65 and above will expand from roughly 830 million in 2025 to 1.1 billion by 2035, and AMD prevalence rises sharply past that threshold [[3]](https://healthdata.org). Medicare Part B spending on intravitreal anti-VEGF injections exceeded USD 3.1 billion in 2024, a figure that sharpens payer interest in low-cost preventative nutrition upstream of injection therapy [[5]](https://cms.gov).

### Screen Exposure and the Working-Age Consumer

Adults now report an average of 6 hours 40 minutes of daily screen exposure across work and leisure devices, according to Vision Council survey work covering 10,000 respondents [[7]](https://thevisioncouncil.org). That behavioural shift pulled a younger buyer into a category historically anchored to geriatric AMD management. Brands responded with lower-dose lutein and astaxanthin blends positioned for fatigue and contrast sensitivity rather than disease modification, widening the addressable base by an estimated 22% between 2022 and 2025.

### Subscription Commerce and Retention Economics

Digital-native brands cut customer acquisition cost meaningfully by shifting from one-off transactions to 90-day refill cycles, and observed repeat-purchase rates above 60% in the second year. Retention matters disproportionately here because clinical benefit accrues over 18 to 24 months of continuous use, so subscription mechanics align commercial incentives with the efficacy story the category needs.

### Ingredient Supply Economics

Fermentation-derived algal oil reached broad cost parity with refined fish oil during 2024 as three new production lines came online in the United States and Portugal [[14]](https://goedomega3.com). GOED trade data shows marine omega-3 concentrate pricing swung 31% between 2022 and 2024 on Peruvian anchovy quota decisions [[15]](https://gob.pe/produce). Algal alternatives dampen that volatility while removing mercury and traceability objections that had capped premium pricing.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Regulatory scrutiny of health claims | −0.9 pp | Europe, North America | Medium-term (2–4 yr) | [6] |
| Marine raw-material price volatility | −0.7 pp | Global | Short-term (≤2 yr) | [15] |
| Evidence gaps outside AMD indications | −0.6 pp | Global | Medium-term (2–4 yr) | [2] |
| Private-label price compression | −0.5 pp | North America, Europe | Short-term (≤2 yr) | [11] |
| Fragmented cross-border e-commerce compliance | −0.4 pp | Asia-Pacific, MEA | Long-term (≥4 yr) | [18] |

### Claim Substantiation Under European Scrutiny

EFSA has authorised only a narrow set of eye-related claims, and DHA-linked vision claims carry a 250 mg daily intake condition that many mass-market SKUs do not meet [[6]](https://efsa.europa.eu). Marketers therefore lean on generic wellness language in the European Union, which weakens conversion at shelf. Enforcement is tightening elsewhere too: the US Federal Trade Commission secured settlements exceeding USD 12 million across supplement advertising cases in 2024 [[17]](https://ftc.gov).

### Thin Evidence Beyond Macular Disease

Clinical support outside AMD remains uneven. Systematic reviews of lutein for digital eye strain report small effect sizes and heterogeneous endpoints, and ophthalmology societies have declined to issue formal recommendations for dry eye or cataract prevention [[2]](https://who.int). Sceptical clinicians consequently withhold the referral behaviour that drives pharmacy volume, capping the pace at which newer indications convert interest into recurring revenue.

### Private-Label Erosion at Mass Retail

Retailer own-brand AREDS2 equivalents now undercut national brands by 35% to 45% on a per-day-of-therapy basis in US drug chains [[11]](https://.com). Because the formulation is effectively a published specification, differentiation depends on bioavailability data and brand trust rather than composition — a difficult argument to win in a two-second shelf decision.

## Opportunities

## Eye Health Supplements Market Opportunities

### Pediatric Myopia Franchises in Asia

China's national myopia prevention programme targets a measurable reduction in juvenile myopia prevalence and has embedded annual vision screening into school health checks reaching over 100 million students [[4]](https://iapb.org). That screening infrastructure creates a diagnosed, parent-funded cohort with no established supplement standard of care. Brands that pair low-dose formulations with optometrist co-marketing can claim first-mover position in the fastest-growing indication of the Eye Health Supplements Market.

### Clinician-Channel Formulations

Ophthalmology and optometry practices dispense directly in the United States, Australia and Japan, capturing margin that retail cannot. Practice-dispensed SKUs command 40% to 55% higher realised price per unit than equivalent mass-market products [[11]](https://.com). Building a dedicated professional line — separate packaging, separate pricing, clinical detail aids — protects brand equity from the private-label pressure described in Section 5.3.

### Adherence Data as a Commercial Asset

Subscription platforms generate longitudinal adherence records that no traditional retailer holds. Aggregated and de-identified, that dataset supports real-world evidence submissions, payer pilots and pharmaceutical co-marketing partnerships. Several vision support supplements brands have begun licensing anonymised adherence cohorts to device makers building home monitoring tools, converting operational exhaust into a second revenue line within the Eye Health Supplements Market.

### Emerging-Market Diabetic Retinopathy Programmes

India's National Programme for Control of Blindness screened over 32 million people for diabetic eye disease across recent cycles, and Gulf states have layered retinopathy checks onto national diabetes registries [[4]](https://iapb.org)[[19]](https://diabetesatlas.org). Diagnosed diabetics represent a compliant, physician-influenced buyer group in markets where general supplement penetration stays under 12%. Local manufacturing partnerships keep price points below USD 6 per month, the practical affordability ceiling.

### Fermentation-Sourced Ingredient Vertical Integration

Brands that secure equity or offtake positions in algal DHA and fermented zeaxanthin capacity insulate gross margin from marine volatility. Two ingredient houses opened capacity in 2025 with combined nameplate output sufficient to supply an estimated 18% of global category demand [[14]](https://goedomega3.com).

## Future Outlook

## Eye Health Supplements Market Future Outlook

### Personalised Formulation and Genotype Screening

Complement factor H and ARMS2 genotyping is moving from research settings into consumer testing panels, and zinc dosing response appears to vary by genotype in AREDS reanalyses [[1]](https://nei.nih.gov). Expect tiered SKUs by 2029 in which a low-cost genetic screen routes buyers toward high-zinc or zinc-free formulations. The Eye Health Supplements Market gains pricing headroom from that segmentation because personalisation justifies a premium that commodity AREDS2 clones cannot support.

### Retail Media and Platform Economics

Amazon, Tmall and Shopee now capture a growing slice of category margin through retail media rather than shelf fees. Advertising cost as a share of net revenue for digital-first supplement brands rose from roughly 19% to 28% between 2021 and 2025. Winners will be those with owned subscription bases large enough to dilute paid acquisition, which favours consolidation among mid-sized brands.

### Sustainability and Marine Sourcing Disclosure

Retailer sourcing policies increasingly require MSC or equivalent certification for marine ingredients, and the FAO reports that 37.7% of assessed fish stocks are harvested at biologically unsustainable levels [[13]](https://fao.org). Algal and yeast-fermented alternatives sidestep the audit burden entirely. Expect fermentation-derived DHA to exceed a third of category omega-3 volume before 2033.

## Segment Insights

## Eye Health Supplements Market Segmentation

Segmentation in the Eye Health Supplements Market follows five commercially meaningful dimensions, each with distinct margin and channel behaviour.

### By Ingredient Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Omega-3 Fatty Acids | 31.6% share | Dry eye and general retinal support [1] |
| Carotenoids (Lutein & Zeaxanthin) | 10.5% CAGR | Macular pigment optical density evidence [1] |
| Antioxidant Vitamins (A, C, E) | USD 0.54 Billion | AREDS2 core formulation |
| Zinc & Mineral Complexes | 10.7% share | AMD progression protocols |
| Herbal & Botanical Extracts | 7.9% share | Bilberry and saffron consumer familiarity |
| Others | USD 0.13 Billion | Astaxanthin, NAC and emerging actives |

Omega-3 retains leadership within the Eye Health Supplements Market because it serves two indications at once — dry eye symptom relief and long-term retinal maintenance — giving it the broadest clinician recommendation footprint. Carotenoids grow faster. Macular pigment measurement gave lutein and zeaxanthin an objective biomarker that competing actives lack, and marketers use it heavily. Ingredient houses have also solved the stability problems that once forced high overages, improving formulation cost by roughly 15% since 2022 [[14]](https://goedomega3.com).

### By Form

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Softgel Capsules | 48.7% share | Oil-soluble carotenoid and DHA delivery |
| Tablets | 20.3% share | Lowest cost per day of therapy |
| Gummies & Chews | 11.5% CAGR | Pediatric and adherence-driven adoption [9] |
| Powders & Liquids | USD 0.28 Billion | Geriatric swallowing difficulty |
| Others | 7.2% share | Sachets, sprays, functional beverages |

Softgels dominate because carotenoids and marine oils are lipophilic and behave predictably in an oil matrix. Chews closed most of the bioavailability gap once pectin encapsulation matured, and they solve the adherence problem that undermines a 24-month therapy story. Pediatric myopia demand accelerates that shift further.

### By Indication

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Age-Related Macular Degeneration | USD 1.22 Billion | AREDS2 clinical protocol [1] |
| Dry Eye | 19.6% share | Screen exposure and ageing tear film [7] |
| Cataract | 14.8% share | Antioxidant prevention positioning |
| Diabetic Retinopathy | 10.3% share | Diabetes registry screening [19] |
| Myopia Progression | 11.6% CAGR | School screening programmes in Asia [4] |
| Others | 5.7% share | Glaucoma support, post-surgical recovery |

AMD anchors the Eye Health Supplements Market and will keep doing so, but its share erodes gradually as newer indications recruit younger buyers. Myopia is the segment to watch. It is the only indication where a national government has effectively created the demand, and pediatric buyers imply a two-decade purchase horizon rather than the five-to-eight years typical of an AMD patient.

### By Distribution Channel

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| OTC Pharmacy & Drug Stores | 45.5% share | Pharmacist recommendation [11] |
| Online Retail & DTC | 12.9% CAGR | Subscription refill economics |
| Supermarkets & Hypermarkets | 15.1% share | Private-label ocular nutritional supplements |
| Specialty & Health Stores | USD 0.27 Billion | Premium and clean-label positioning |
| Others | 5.3% share | Practice dispensing, hospital pharmacy |

The distribution channel market data highlights various retail segments and their primary demand drivers. OTC Pharmacy and Drug Stores lead with a specific share driven by pharmacist recommendations. Online Retail and DTC expand via subscription refill economics. Supermarkets and Hypermarkets hold a distinct share driven by private-label ocular nutritional supplements, while Specialty and Health Stores and Others focus on clean-label positioning and practice dispensing.

### By Age Group

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Adults | 64.8% share | Digital eye strain and preventative use [7] |
| Geriatric | USD 0.77 Billion | AMD and cataract management [3] |
| Pediatric | 9.9% CAGR | Myopia screening programmes [4] |

The age group market segmentation outlines three main categories and their primary demand drivers. Adults account for a major share driven by digital eye strain and preventative use [[7]](https://thevisioncouncil.org). The geriatric segment is measured in market value, driven by age-related macular degeneration and cataract management. Finally, the pediatric segment grows through dedicated myopia screening programmes.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.2% share | Pharmacy detailing, practice dispensing, subscription DTC |
| Europe | USD 0.77 Billion | Claim-compliant reformulation, pharmacy chains |
| Asia-Pacific | 9.3% CAGR (2026–2035) | Pediatric myopia, cross-border e-commerce |
| South America | 5.8% share | Modern-trade expansion, local contract manufacturing |
| Middle East & Africa | USD 0.13 Billion | Diabetes registries, premium import channels |
| Total | USD 2.91 Billion | — |

Geographic performance in the Eye Health Supplements Market tracks three variables: pharmacy density, out-of-pocket health spending, and whether national screening programmes create diagnosed demand.

### North America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 78.4% of region | AREDS2 clinician recommendation base [1] |
| Canada | USD 0.13 Billion | NNHPD product licensing clarity [16] |
| Mexico | 9.1% CAGR | Pharmacy chain modernisation [11] |

Pharmacy remains the decisive channel across North America, where PreserVision-class formulations enjoy a two-decade recommendation habit among retina specialists. The Eye Health Supplements Market here is mature but not static: subscription DTC entrants captured meaningful incremental share between 2023 and 2025 without materially shrinking pharmacy volume, suggesting category expansion rather than pure substitution. Canada's Natural Health Products framework offers pre-market licensing that reduces claim ambiguity relative to the US structure-function regime [[16]](https://canada.ca).

### Europe

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 21.6% of region | Apotheke recommendation culture |
| UK | USD 0.14 Billion | High-street optician dispensing |
| France | 17.2% of region | Pharmacist-led parapharmacie sales |
| Italy | 8.9% of region | Integratori category familiarity |
| Spain | USD 0.05 Billion | Ageing coastal demographics |
| Nordic Countries | 7.4% CAGR | Marine omega-3 heritage brands [15] |
| Russia | 5.8% of region | Domestic manufacturing substitution |
| Rest of Europe | 9.3% of region | Cross-border pharmacy e-commerce |

Claim restriction shapes European commercial strategy more than demand does. German Apotheken sustain the region's highest per-capita spend because pharmacists actively recommend, compensating for advertising limits imposed under Regulation 1924/2006 [[6]](https://efsa.europa.eu). Nordic manufacturers leverage established marine oil supply relationships, though the same anchovy quota exposure described in Section 5 applies.

### Asia-Pacific

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 34.8% of region | National juvenile myopia programme [4] |
| India | 10.8% CAGR | Diabetic retinopathy screening scale-up [19] |
| Japan | USD 0.15 Billion | FOSHU-labelled functional foods [20] |
| South Korea | 9.6% of region | Health functional food certification |
| ASEAN | 10.1% CAGR | Modern-trade pharmacy growth |
| Rest of Asia-Pacific | USD 0.06 Billion | Cross-border platform imports |

Asia-Pacific supplies the growth story for the Eye Health Supplements Market. China's school screening apparatus produces diagnosed pediatric demand at a scale no other geography matches, and platform commerce moves product without the pharmacy detailing costs required in the West [[4]](https://iapb.org). Japan's FOSHU system permits specified health claims that European regulators would refuse, giving Japanese brands unusual latitude in on-pack communication [[20]](https://caa.go.jp).

### South America

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.3% of region | ANVISA supplement framework harmonisation [21] |
| Argentina | USD 0.03 Billion | Import substitution manufacturing |
| Rest of South America | 7.9% CAGR | Chain pharmacy penetration |

Brazil anchors the region after ANVISA consolidated food supplement rules into a single registration pathway, cutting time-to-shelf for imported eye formulations [[21]](https://gov.br/anvisa). Currency volatility remains the practical constraint, pushing multinationals toward local contract manufacturing rather than finished-goods import.

### Middle East & Africa

| Country | Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.9% of region | Vision 2030 preventative health spend [22] |
| UAE | USD 0.03 Billion | Premium pharmacy retail density |
| South Africa | 8.4% CAGR | Private medical scheme wellness benefits |
| Egypt | 12.6% of region | Diabetes prevalence above 20% of adults [19] |
| Rest of MEA | USD 0.04 Billion | Gulf re-export distribution hubs |

Gulf states buy premium and buy imported. Saudi Arabia's health transformation programme funds preventative screening that surfaces diabetic eye disease earlier, and Saudi FDA registration now runs a defined electronic pathway that shortened approval timelines materially [[22]](https://sfda.gov.sa). Egypt's scale and diabetes burden make it the region's most underpenetrated opportunity despite constrained per-capita spending.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration is moderate. The estimated top-five share sits near 36%, with an HHI in the 520 to 610 band — fragmented enough that regional specialists survive, concentrated enough that pharmacy shelf space is genuinely contested. Ingredient suppliers hold disproportionate influence in the Eye Health Supplements Market because branded lutein and algal DHA platforms carry the clinical dossiers that finished-goods marketers cite.

| Company | Est. Revenue Share Range | Key Offerings for Eye Health Supplements Market | Strategic Positioning |
| --- | --- | --- | --- |
| Bausch + Lomb | ~10–13% | PreserVision AREDS2, Ocuvite | Clinician-anchored category leader |
| Alcon | ~6–9% | Systane supplements, ICaps line | Eye-care ecosystem bundling |
| Nestlé Health Science | ~5–8% | Nature's Bounty eye formulas | Scale manufacturing and mass retail |
| Amway (Nutrilite) | ~4–7% | Nutrilite Ocular Health | Direct-selling reach in Asia |
| Abbott | ~3–6% | Vision-support nutritional blends | Diabetes-adjacent portfolio pull |
| Blackmores | ~3–5% | Lutein Vision Advanced | Pharmacy trust in APAC |
| H&H Group (Swisse) | ~2–4% | Swisse Ultiboost Lutein | Cross-border e-commerce into China |
| ZeaVision | ~2–4% | EyePromise practice-dispensed range | Optometry channel specialist |
| DSM-Firmenich | ~2–4% | Life's DHA algal oil, carotenoids | Upstream ingredient platform |
| Kemin Industries | ~2–4% | FloraGLO Lutein, OmniActive blends | Branded ingredient licensing |
| Thorne | ~1–3% | Clinical-grade eye formulations | Practitioner and testing integration |
| Nordic Naturals | ~1–3% | Omega Vision, algal alternatives | Sustainability-led premium |

## Recent News & Developments

## Recent News & Developments

- Bausch + Lomb (March 2024): Expanded PreserVision chewable formats across US drug chains, targeting adherence gaps among patients unable to tolerate large softgels [[11]](https://.com)
- DSM-Firmenich (September 2024): Commissioned additional algal DHA fermentation capacity, reducing dependence on Peruvian anchovy landings for pharmaceutical-grade oil [[14]](https://goedomega3.com)
- China National Health Commission (January 2024): Broadened juvenile vision screening requirements to additional provincial school systems, enlarging the diagnosed pediatric cohort [[4]](https://iapb.org)

- EFSA (November 2023): Issued updated guidance clarifying substantiation requirements for vision-related claims, prompting reformulation across European ranges [[6]](https://efsa.europa.eu)

- H&H Group (October 2024): Expanded Swisse cross-border operations on Chinese platforms, prioritising eye-health SKUs for the pediatric and student segments [[4]](https://iapb.org)

## Report Scope

## Eye Health Supplements Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global eye health supplements across ingredient type, form, indication, distribution channel, age group and geography |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 8.05% (2026–2035) |
| Market Size Checkpoints | USD 2.91 Billion (2025); USD 3.15 Billion (2026); USD 6.32 Billion (2035) |
| Fastest Growing Segments | Carotenoids; Gummies & Chews; Myopia Progression; Online Retail & DTC; Pediatric; Asia-Pacific |
| Companies Profiled | 12 leading participants in the Eye Health Supplements Market |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: What should procurement teams verify before contracting lutein supply for the Eye Health Supplements Market?**
A: Demand certificates of analysis showing isomer ratio, marigold origin traceability, and residual solvent testing. Branded platforms carry clinical dossiers that generic extract does not, which matters if you plan claim-adjacent marketing [14].

**Q: How do private-label contracts differ from branded supply agreements?**
A: Private-label deals typically shift formulation liability to the contract manufacturer but retain claim liability with the retailer. Minimum order quantities run three to five times higher, and exclusivity windows rarely exceed 18 months [11].

**Q: Which certifications matter most for exporters entering the Eye Health Supplements Market?**
A: Marine Stewardship Council or Friend of the Sea for fish-derived oils, plus destination-specific registration — NNHPD in Canada, FOSHU notification in Japan, ANVISA in Brazil. Skipping local registration is the most common entry failure [16][20][21].

**Q: Is algal DHA genuinely cost-competitive with refined fish oil now?**
A: At pharmaceutical concentration grades, yes — parity was reached during 2024. At lower concentrations, fish oil still holds a modest cost advantage that narrows with each new fermentation line [14].

**Q: What integration challenges face retailers adding clinical formulas to the Eye Health Supplements Market?**
A: Pharmacist training is the bottleneck, not shelf space. Clinical SKUs require dosing conversations and contraindication awareness, particularly zinc interactions and anticoagulant considerations with high-dose omega-3 [1].

**Q: How should investors assess subscription churn in this category?**
A: Look at month-13 retention rather than month-3. Benefit accrues slowly, so early churn reflects marketing mismatch while late churn reveals whether the clinical promise held the customer [12].

**Q: What liability exposure comes from structure-function claims?**
A: Enforcement targets implied disease treatment language most aggressively. Substantiation files must predate the claim, and testimonial advertising has drawn recent regulatory action even where the underlying formulation was compliant [17].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/eye-health-supplements-market-8788*